Medically reviewed by David Ozeri, MD
IgA nephropathy (IgAN), also known as Berger’s disease, is considered a rare disease. However, it is the leading cause of kidney inflammation (glomerulonephritis) worldwide. Cases of IgAN appear to be rising, but experts believe this reflects better detection and reporting, rather than an increase in risk.
IgA nephropathy occurs when abnormal IgA antibodies get stuck in your glomeruli (tiny kidney filters), causing inflammation. The inflammation causes blood and protein to leak into your urine and weakens your kidney function.
About 60 out of every 100,000 people worldwide have IgA nephropathy. In the United States, roughly 150,000- 200,000 people have IgAN.
Globally, there are an average of two or three new cases per 100,000 people each year. Rates are the highest in East Asia. Here are the estimated annual new case rates per 100,000 people across several countries and continents:
Reported rates of IgA nephropathy vary widely by region, but these differences do not always reflect disease risk. Genetics and ethnicity are part of the equation, but how countries screen, diagnose, and track cases strongly shapes the numbers.
IgA nephropathy appears to be more common in East and Pacific Asian countries, suggesting a higher underlying disease burden in these regions. However, screening practices also influence reported rates.
In countries such as Japan, routine urine testing begins in childhood. This allows healthcare providers to detect kidney changes early and diagnose IgA nephropathy in people with mild or no symptoms. In many other regions, providers do not routinely screen healthy people, so cases often go undetected until a person has symptoms.
A kidney biopsy is the only way to confirm IgAN. A kidney biopsy is when providers use a needle to remove a piece of kidney tissue for examination under a microscope. Because biopsies are invasive and not always available, many people never receive a formal diagnosis. Milder cases are often missed, while more severe cases are more likely to appear in official statistics.
Some researchers track incidence, which is the number of new diagnoses each year. Others measure prevalence, or the number of people who live with the disease. Estimating these numbers is difficult because many people have no symptoms, a diagnosis requires a kidney biopsy, and screening and access to care vary.
Many gather data from kidney biopsy registries, national databases, or insurance claims. These sources reflect who gets tested and diagnosed but don't reflect everyone who has the disease. As a result, lower reported rates in regions such as South Africa may reflect underdiagnosis rather than lower risk.
Most studies focus on Asia, Europe, and North America. Very little data exist from Africa or from Black, Hispanic, and Latino populations. These gaps limit what researchers can conclude and highlight the need for larger, more diverse studies with equal access to kidney testing.
Anyone can develop IgA nephropathy, but the likelihood varies based on:
Contact a healthcare provider if you notice symptoms of IgAN, such as:
Your provider may use risk assessment tools that combine lab results, blood pressure, and medical history. If you are at high risk, they may periodically check your urine for protein and monitor your kidney function through blood tests.
Read the original article on Health
2026-01-15T18:49:40Z